Novartis AG ADR (NVS)
NYSE · Healthcare · Drug Manufacturers - General
Novartis AG ADR is a Healthcare company with a market capitalization of $287.36B, a trailing P/E ratio of 22.9, and a dividend yield of 3.15%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q2 2026 | July 21, 2026 | $2.41 | $2.20 | +9.6% |
| Q1 2026 | April 28, 2026 | $1.65 | $1.65 | +0.0% |
| Q4 2025 | February 4, 2026 | $2.03 | $2.00 | +1.5% |
| Q3 2025 | October 28, 2025 | $2.25 | $2.31 | -2.6% |
| Q2 2025 | July 17, 2025 | $2.42 | $2.37 | +2.1% |
| Q1 2025 | April 29, 2025 | $2.28 | $2.17 | +5.1% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 5,713,789 | 0.30% | 3.6 | +6.7% |
| June 30, 2026 | 5,355,498 | 0.28% | 2.0 | +2.1% |
| June 15, 2026 | 5,246,790 | 0.27% | 2.6 | +15.5% |
| May 29, 2026 | 4,543,531 | 0.24% | 3.7 | +1.5% |
| May 15, 2026 | 4,475,369 | 0.23% | 3.5 | -0.3% |
| April 30, 2026 | 4,488,888 | 0.23% | 3.0 | -22.4% |
| April 15, 2026 | 5,785,672 | 0.30% | 3.9 | -7.5% |
| March 31, 2026 | 6,255,669 | 0.32% | 3.4 | -17.0% |
Other Drug Manufacturers - General Stocks
Frequently Asked Questions
What is Novartis AG ADR's market cap?
As of August 13, 2026, Novartis AG ADR (NVS) has a market capitalization of $287.36B.
What is Novartis AG ADR's P/E ratio?
Novartis AG ADR trades at a trailing price-to-earnings (P/E) ratio of 22.9. Its forward P/E is 16.9.
Does Novartis AG ADR pay a dividend?
Yes — Novartis AG ADR pays a dividend yielding 3.15%, an annual payout of $4.67 per share.
What sector is NVS in?
Novartis AG ADR is in the Healthcare sector, specifically the Drug Manufacturers - General industry.
What is Novartis AG ADR's short interest?
As of the July 15, 2026 FINRA settlement, 5,713,789 NVS shares were sold short, or 0.30% of shares outstanding. Days to cover: 3.6. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Novartis AG ADR's revenue?
In its latest reported fiscal year (ending December 31, 2025), Novartis AG ADR reported revenue of $54.81B and net income of $14.06B.
Ask your own questions about NVS
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.